Исследование блокаторов в Тавистоке не нашло психологической пользы — но 98% перешли на гормоны противоположного пола

Краткосрочные результаты подавления пубертата в отобранной когорте 12–15-летних молодых людей со стойкой гендерной дисфорией в Великобритании

Когортные и регистровые исследования Блокаторы полового созревания Психическое здоровье и суицид

Authors: Polly Carmichael, Gary Butler, Una Masic, Tim J. Cole, Bianca L. De Stavola, Sarah Davidson, Elin M. Skageberg, Sophie Khadr, Russell M. Viner
Journal: PLOS ONE
Year: 2021
Source: https://doi.org/10.1371/journal.pone.0243894

Summary

This was the UK's own test of puberty blockers, run by the Tavistock's gender clinic for children from 2011. Forty-four carefully chosen 12–15-year-olds were given a blocker drug and followed until they were over 16. The blockers paused puberty as intended. But there was no measurable change in emotional distress, self-harm, quality of life or gender distress, and bone density fell behind other teens their age. Most young people spoke positively about the treatment in interviews, and 43 of 44 went on to cross-sex hormones. The authors call for larger studies. There was no comparison group, numbers fell sharply after the first year, and a later re-analysis found up to a third got worse. So the study offers no evidence that blockers help mental health.

Key findings

44 молодых человека 12–15 лет (25 рождены мужчинами, 19 женщинами) с тяжёлым, длительным гендерным дистрессом начали блокатор пубертата между 2011 и 2015 годами, обычно после двух лет оценки в клинике.
Ни родители, ни сами молодые люди не сообщили об изменениях в эмоциональных проблемах и проблемах поведения или в самоповреждении через 1, 2 или 3 года.
Качество жизни, чувства по поводу тела, гендерный дистресс и то, как они справлялись (по оценке клиницистов), тоже изменились мало; авторы отмечают, что блокаторы не меняют тело в сторону желаемого пола.
Плотность костей в пояснице росла медленнее, чем у других подростков, поэтому отставала от возрастной нормы, а рост в высоту тоже замедлился.
Ожидаемые побочные эффекты, такие как головные боли, приливы жара и усталость, были частыми; 38% сказали, что у них низкая энергия, в интервью через 15–24 месяца.
43 из 44 (98%) перешли на кросс-половые гормоны, что соответствует нидерландскому результату, что почти никто не прекращает после блокаторов.
В данных через 2 года оставалось лишь 24 молодых человека, а через 3 года — 14 (причём лишь 6 заполнили собственные опросники через 3 года), поэтому о более долгосрочных эффектах мало что можно сказать.
Повторный анализ тех же данных 2024 года, проведённый Макферсоном и Фридманом, показал, что у 15–34% молодых людей явно стало хуже, в зависимости от показателя, момента времени и того, кто сообщал.

Abstract

BACKGROUND: In adolescents with severe and persistent gender dysphoria (GD), gonadotropin releasing hormone analogues (GnRHa) are used from early/middle puberty with the aim of delaying irreversible and unwanted pubertal body changes. Evidence of outcomes of pubertal suppression in GD is limited. METHODS: We undertook an uncontrolled prospective observational study of GnRHa as monotherapy in 44 12-15 year olds with persistent and severe GD. Prespecified analyses were limited to key outcomes: bone mineral content (BMC) and bone mineral density (BMD); Child Behaviour CheckList (CBCL) total t-score; Youth Self-Report (YSR) total t-score; CBCL and YSR self-harm indices; at 12, 24 and 36 months. Semistructured interviews were conducted on GnRHa. RESULTS: 44 patients had data at 12 months follow-up, 24 at 24 months and 14 at 36 months. All had normal karyotype and endocrinology consistent with birth-registered sex. All achieved suppression of gonadotropins by 6 months. At the end of the study one ceased GnRHa and 43 (98%) elected to start cross-sex hormones. There was no change from baseline in spine BMD at 12 months nor in hip BMD at 24 and 36 months, but at 24 months lumbar spine BMC and BMD were higher than at baseline (BMC +6.0 (95% CI: 4.0, 7.9); BMD +0.05 (0.03, 0.07)). There were no changes from baseline to 12 or 24 months in CBCL or YSR total t-scores or for CBCL or YSR self-harm indices, nor for CBCL total t-score or self-harm index at 36 months. Most participants reported positive or a mixture of positive and negative life changes on GnRHa. Anticipated adverse events were common. CONCLUSIONS: Overall patient experience of changes on GnRHa treatment was positive. We identified no changes in psychological function. Changes in BMD were consistent with suppression of growth. Larger and longer-term prospective studies using a range of designs are needed to more fully quantify the benefits and harms of pubertal suppression in GD.

Conclusion

Treatment with GnRHa was efficacious in suppressing pubertal progression; anticipated effects of sex-hormone withdrawal were common and there were no unexpected adverse events. BMD increased in the lumbar spine and was stable at the hip, while BMD z-scores fell, consistent with delayed puberty. Overall participant experience was positive, but the authors identified no changes in psychological function, quality of life or degree of gender dysphoria. The great majority went on to cross-sex hormones; one did not, which the authors took as evidence that gender identity development continues on GnRHa. Larger, longer-term studies using a range of designs are needed to quantify benefits and harms.

Methodological limitations

No comparison group: The authors admit that without a comparison group they cannot say what caused what. Mental health, self-harm and bone density all change naturally during the teenage years, so "no change" cannot be read as either benefit or harm.
Small and shrinking group: Only 44 young people took part. Data were available for 24 at 2 years and 14 at 3 years, and the young people's own questionnaires for just 15 at 2 years and 6 at 3 years. With so few, real changes could easily be missed.
Carefully chosen group: To take part, children had to have felt the other gender all their lives, be mentally stable, have no serious mental illness and have had at least six months of assessment. So the results do not apply to most children the clinic saw at the time.
Therapy at the same time: Regular psychological support was required, and local services treated other problems. So any effect of the drug is mixed up with the effect of therapy.
Averages hide people who got worse: A re-analysis of the study's data (McPherson & Freedman, 2024, Journal of Sex & Marital Therapy) found 15–34% clearly got worse, and the number who clearly improved fell toward zero over time.
Published late, and disputed: The study began in 2011 but was not published in a journal until 2021. Michael Biggs had earlier pointed to unpublished 2015 early results suggesting more self-harm and problems in girls; the authors say those data were incomplete and not yet checked.
Problems with the data: The authors report young people got tired of questionnaires, some refused later follow-ups, missing answers made some data unusable, and some detailed data were lost when hospital computer systems changed.
Measures dropped partway: Planned questionnaires on gender distress and a teacher questionnaire were dropped during the study, so fewer things were measured than intended.
Interview findings not tested: The finding that young people had a "positive experience" comes from simple interviews, with nothing to compare against from before treatment, written up in clinic notes rather than using tested questionnaires.
Almost everyone moved on to hormones: With 98% going on to cross-sex hormones, the study gives no support to the idea that blockers are a neutral pause. It cannot tell whether this was due to who was chosen or to the blockers themselves.
Clinic studying its own treatment: The study had no outside funding, was run inside the clinic, and was led by the clinic's director, whose service gave the treatment being tested.

detrans.ai

Summary

Key findings

Abstract

Conclusion